8-Year check: does the hydrus implant keep glaucoma in check?

NCT ID NCT07460791

Recruiting now Disease control Sponsor: Johannes Gutenberg University Mainz Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 glaucoma patients who received a tiny eye implant called Hydrus along with cataract surgery. Researchers want to see if the implant still helps control eye pressure after 8 to 14 years. The goal is to understand how well the implant works over the long term and whether it reduces the need for eye drops.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydrus implant (a tiny stent placed in the eye to help drain fluid) plus cataract surgery (phacoemulsification)
What this could lead to: If successful, this could show that the Hydrus implant provides long-lasting eye pressure control for glaucoma patients, reducing the need for daily eye drops.
What could go wrong: This is an observational follow-up study, not a new treatment test. It only looks back at past results, so it cannot prove the implant works better than other options. Some patients may still need additional treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

Department of Opthalmology
RECRUITING

Mainz, Rhineland-Palatinate, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.